Table 2.
Comparison of demographic and serological parameters between anti-DFS70-positive and anti-DFS70-negative SLE patients.
| Characteristics | Anti-DFS70 positive [n = 176; n (%)] | Anti-DFS70 negative [n = 675; n (%)] | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | |||
| Age (years) a | 38.0 ± 12.7 | 40.7 ± 14.0 | 0.985 (0.973, 0.998) | 0.022 | 0.982 (0.969, 0.995) | 0.007 |
| Sex (women) | 165 (93.8) | 611 (90.5) | 1.571 (0.810, 3.047) | 0.181 | ||
| Duration (years) b | 4.0 (0.9–10.0) | 5.0 (1.0–10.0) | 0.996 (0.972, 1.020) | 0.713 | ||
| SLEDAI-2K b | 8.0 (4.0–11.8) | 7.0 (4.0–12.0) | 1.018 (0.989, 1.048) | 0.219 | ||
| Anti-dsDNA | 117 (66.5) | 326 (48.3) | 2.123 (1.500, 3.005) | <0.0001 | 1.598 (1.107–2.306) | 0.012 |
| Anti-C1q | 60 (34.1) | 150 (22.2) | 1.810 (1.262, 2.597) | 0.001 | ||
| Anti-Sm | 33 (18.8) | 99 (14.7) | 1.343 (0.870, 2.073) | 0.184 | ||
| Anti-nRNP/Sm | 81 (46.0) | 245 (36.3) | 1.496 (1.070, 2.093) | 0.018 | ||
| Anti-Ro52 | 102 (58.0) | 338 (50.1) | 1.374 (0.983, 1.922) | 0.063 | ||
| Anti-SSA/Ro60 | 104 (59.1) | 367 (54.4) | 1.212 (0.866, 1.697) | 0.262 | ||
| Anti-SSB/La | 23 (13.7) | 76 (11.3) | 1.185 (0.719, 1.952) | 0.505 | ||
| Anti-PCNA | 14 (8.0) | 10 (1.5) | 5.747 (2.507, 13.173) | <0.0001 | 6.101 (2.534, 14.688) | <0.0001 |
| Anti-Rib-P | 44 (25.0) | 143 (21.2) | 1.240 (0.841, 1.828) | 0.277 | ||
| Anticardiolipin | 9 (5.1) | 49 (7.3) | 0.689 (0.331, 1.430) | 0.317 | ||
| C3 a (g/L) | 0.7 ± 0.3 | 0.8 ± 0.3 | 0.358 (0.201, 0.638) | 0.0005 | ||
| C4 a (g/L) | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.015 (0.002, 0.143) | 0.0002 | ||
| CRP b (mg/L) | 3.3 (3.1–9.1) | 3.2 (2.9–8.5) | 0.996 (0.988, 1.005) | 0.389 | ||
| ESR a (mm/h) | 43.7 ± 33.0 | 36.2 ± 28.5 | 1.008 (1.003, 1.013) | 0.003 | ||
| Serum IgA a (g/L) | 2.9 ± 1.4 | 2.6 ± 1.3 | 1.166 (1.039, 1.308) | 0.009 | ||
| Serum IgG a (g/L) | 17.0 ± 7.6 | 13.1 ± 5.6 | 1.095 (1.066, 1.125) | <0.0001 | 1.097 (1.067, 1.129) | <0.0001 |
| Serum IgM a (g/L) | 1.1 ± 0.7 | 1.0 ± 0.7 | 1.202 (0.962, 1.502) | 0.105 | ||
| Prednisone dose b (mg) | 30 (15–60) | 30 (12.5–40) | 1.002 (0.999, 1.006) | 0.203 | ||
| Hydroxychloroquine | 111 (63.1) | 411 (60.9) | 1.097 (0.778, 1.546) | 0.597 | ||
| Mycophenolate mofetil | 21 (11.9) | 101 (15.0) | 0.770 (0.466, 1.273) | 0.308 | ||
| Cyclophosphamide | 10 (5.7) | 45 (6.7) | 0.843 (0.416, 1.709) | 0.636 | ||
| Tacrolimus | 8 (4.5) | 33 (4.9) | 0.926 (0.420, 2.043) | 0.850 | ||
| Cyclosporin A | 7 (4.0) | 22 (3.3) | 1.229 (0.517, 2.926) | 0.641 | ||
| Azathioprine | 2 (1.1) | 18 (2.7) | 0.420 (0.096, 1.825) | 0.247 | ||
| No immunosuppressants at present | 38 (21.6) | 157 (23.3) | 0.909 (0.608, 1.357) | 0.639 | ||
p < 0.05 is shown in bold.
C3, complement 3; C4, complement 4; CRP, C-reactive protein; DFS70, dense fine speckles 70; ds-DNA, double-stranded DNA; ESR, erythrocyte sedimentation rate; OR, odds ratio; PCNA, proliferating cell nuclear antigen; Rib-P, ribosomal-P; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
a
Average ± standard deviation.
b
Median (interquartile range).